Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein
Abstract
One of the most common molecular abnormalities in human cancers involves over-expression of the c-Myc oncoprotein. By regulating the expression of key cellular genes, c-Myc controls a number of normal biological properties such as cell cycle entry, differentiation, growth, and the decision to die or remain viable. All of these functions require that C-Myc physically associate with another protein. Max. Example of diseases in which c-Myc deregulation occurs include breast cancer (approx. 30% of cases), colon cancer (>85%), and Burkitt's lymphoma (>98&). Of relevance to proposal is that at least 25% of prostate cancers are also associated with c-Myc deregulation. Additional evidence suggests that more advanced/aggressive disease may also be more commonly associated with c-Myc over-expression. Because nearly 190,000 men in the United States alone will be diagnosed with prostate cancer this year, and over 30,000 will die, the design of drugs that inhibit c-Myc would appear to be a reasonable approach.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2005
- Accession Number
- ADA434552
Entities
People
- Edward V. Prochownik